Cargando…

Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia

Using ex vivo drug screening of primary patient specimens, we identified the combination of the p38 MAPK inhibitor doramapimod (DORA) with the BCL2 inhibitor venetoclax (VEN) as demonstrating broad, enhanced efficacy compared with each single agent across 335 acute myeloid leukemia (AML) patient sam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurtz, Stephen E., Eide, Christopher A., Kaempf, Andy, Long, Nicola, Bottomly, Daniel, Nikolova, Olga, Druker, Brian J., McWeeney, Shannon K., Chang, Bill H., Tyner, Jeffrey W., Agarwal, Anupriya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Stimulus Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131911/ https://www.ncbi.nlm.nih.gov/pubmed/35078224 http://dx.doi.org/10.1182/bloodadvances.2021006307

Ejemplares similares

A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia
por: Damnernsawad, Alisa, et al.
Publicado: (2020)

Immune cell proportions correlate with clinicogenomic features and ex vivo drug responses in acute myeloid leukemia
por: Romine, Kyle A., et al.
Publicado: (2023)

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
por: Rice, William G., et al.
Publicado: (2022)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

HitWalker: variant prioritization for personalized functional cancer genomics
por: Bottomly, Daniel, et al.
Publicado: (2013)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

Lasting shift in the gut microbiota in patients with acute myeloid leukemia
por: Rashidi, Armin, et al.
Publicado: (2022)

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
por: Tiong, Ing S., et al.
Publicado: (2021)

Vesicular trafficking is a key determinant of the statin response in acute myeloid leukemia
por: Krosl, Jana, et al.
Publicado: (2022)

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine
por: Bottomly, Daniel, et al.
Publicado: (2013)

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
por: Chua, Chong Chyn, et al.
Publicado: (2022)

CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes
por: Huang, Benjamin J., et al.
Publicado: (2021)

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes
por: Tsai, Harrison K., et al.
Publicado: (2022)

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
por: Dennis, Mike, et al.
Publicado: (2021)

Comprehensive molecular characterization of a rare case of Philadelphia chromosome–positive acute myeloid leukemia
por: Rosenberg, Mara W., et al.
Publicado: (2022)

Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia
por: Lamble, Adam J., et al.
Publicado: (2020)

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
por: Hu, Yixin, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
por: Saygin, Caner, et al.
Publicado: (2022)

Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods
por: Kotrová, Michaela, et al.
Publicado: (2022)

Validation and clinical application of transactivation assays for RUNX1 variant classification
por: Decker, Melanie, et al.
Publicado: (2022)

Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

A novel class of ZNF384 aberrations in acute leukemia
por: Zaliova, Marketa, et al.
Publicado: (2021)

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
por: Moskop, Amy, et al.
Publicado: (2022)

Gata2 haploinsufficiency promotes proliferation and functional decline of hematopoietic stem cells with myeloid bias during aging
por: Abdelfattah, Ali, et al.
Publicado: (2021)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

plethy: management of whole body plethysmography data in R
por: Bottomly, Daniel, et al.
Publicado: (2015)

HitWalker2: visual analytics for precision medicine and beyond
por: Bottomly, Daniel, et al.
Publicado: (2016)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2022)

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse
por: Samra, Bachar, et al.
Publicado: (2021)

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
por: Zhang, Haijiao, et al.
Publicado: (2019)

Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2022)

Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method
por: Vachon, Celine M., et al.
Publicado: (2022)

Identification of β-catenin binding regions in colon cancer cells using ChIP-Seq
por: Bottomly, Daniel, et al.
Publicado: (2010)

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples
por: Edwards V, David K., et al.
Publicado: (2018)

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia
por: Watanabe-Smith, Kevin, et al.
Publicado: (2016)

Lineage switching of the cellular distribution of BRAF(V600E) in multisystem Langerhans cell histiocytosis
por: Milne, Paul, et al.
Publicado: (2022)

Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations
por: Zhang, Haijiao, et al.
Publicado: (2017)

Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
por: Thieme, Elana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3othau0aam6due380rrcaj3ums